光音響イメージングの世界市場予測（2022年～2027年）

世界の光音響イメージングの市場規模は、予測期間中に23.32%のCAGRで成長が予測されています。

当レポートでは、世界の光音響イメージング市場について調査分析し、市場概要、市場力学、市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場の内訳

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • エンドユーザーの交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 業界での競争企業間の敵対関係
• 業界バリューチェーン分析

第5章 光音響イメージング市場分析：製品別

• イントロダクション
• 光音響トモグラフィー
• 光音響顕微鏡

第6章 光音響イメージング市場分析：タイプ別

• イントロダクション
• 前臨床
• 臨床

第7章 光音響イメージング市場分析：用途別

• イントロダクション
• 腫瘍学
• 心臓病学
• 血管学
• 組織学
• インターベンショナルラジオロジー
• その他の用途

第8章 光音響イメージング市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • その他
• 中東・アフリカ
  • サウジアラビア
  • イスラエル
  • その他
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • インドネシア
  • タイ
  • 台湾
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場収益性
• 合併・買収・合意・提携
• ベンダーの競合マトリクス

第10章 企業プロファイル

• Advantest Corp.
• TomoWave
• Kibero GmbH
• FUJIFILM VisualSonics Inc.
• Seno Medical Instruments
• iThera Medical GmbH
• Aspectus GmbH
• Vibronix Inc.
• ENDRA Life Sciences Inc.
• PA Imaging R&D B.V.

The photoacoustic imaging market is projected to grow at a CAGR 23.32% during the forecast period.

Photoacoustic imaging is a non-invasive biomedical imaging technique that generates ultrasonic waves by irradiating a material with a pulsed laser and reconstructing an image of the tissue's light energy absorption pattern.

The rising incidence of cancer, particularly breast cancer, and the increasing number of research projects in the fields of non-ionizing radiation for imaging are propelling the market forward. According to the WHO, around 2.3 million women were diagnosed with breast cancer in 2020, with 685,000 fatalities worldwide. Furthermore, the expanding scope of applications is contributing to market growth. Photoacoustic Imaging (PAI) is superior to other diagnostic imaging methods because it examines tissues in real-time with excellent resolution and contrast at long penetration depths and allows morphological, functional, and molecular imaging of living people.

It also features improved handling and diagnostic accuracy, as well as higher imaging speed and sensitivity. One of the most significant benefits of PAI is that it can be easily implemented on clinical ultrasound machines, allowing cellular and molecular imaging to be added to the typical ultrasound imaging range.

However, factors such as the expensive cost of these systems, and limited bandwidth, which makes them unable to detect signals outside the sensor's frequency range, acquisition time, and ANSI laser safety requirements, may limit market expansion over the forecast period.

Over the forecast period, the photoacoustic tomography (PAT) segment is anticipated to dominate the market, with a considerable CAGR, by product category. With the fewest practical constraints on imaging performance, PAT is the most generic & least stringent photoacoustic imaging technology. In terms of spatial resolution, frame rates, and detection sensitivity, PAT technology has been quickly improving. The use of PAT in basic biological sciences has increased significantly, and various clinical applications have been proposed. PAT is also projected to have more efficient uses in biomedical research and clinical practice owing to its unique combination of optical absorption contrast with ultrasonic imaging depth and resolution scalability.

With a significant revenue share, the oncology segment dominated the market by application. Breast cancer imaging is a potentially important clinical use for PAI in oncology. In terms of clinical application, breast imaging is the most advanced PAI technology, with advantages such as non-contrast imaging of the valves in the heart around a tumor and oxygen saturation mapping. PAI can detect cancers in radiologically dense breasts without inflicting painful breast compression, as opposed to x-ray imaging. This technology has gained favor in recent years since it allows for the precise and early detection of cancer, neurological issues, and vascular abnormalities.

By type, the pre-clinical category accounted for the majority of market revenue. PAI is a non-invasive, non-ionizing technology that can be used to characterize small animals like mice or rats in pre-clinical trials without injuring them. It is possible to characterize small-animal models of brain damage and disease processes, particularly those that require the study of vascular anatomy and function, such as stroke, epilepsy, and traumatic brain injury. PAI's increasing application in research platforms to examine human disease processes and create new therapeutics is predicted to drive market expansion.

North America is predicted to increase at a substantial rate over the projection period. The region's vast number of market competitors, as well as the rising number of cancer patients, appear to be contributing factors to regional market growth. According to the National Cancer Institute, an estimated 1,806,590 new cancer cases were diagnosed in the United States year 2020. Furthermore, increased financing has enhanced the region's scientific efforts. The US spends the most per capita on healthcare and has the greatest cash and grants for research available through government bodies such as the National Institutes of Health (NIH).

Furthermore, Due to the increased need for better imaging equipment and the increasing frequency of research activities, the PAI market in the Asia Pacific is expected to grow at a quick rate over the forecast period. For example, a group of researchers from Pohang University of Science and Technology (POSTECH) in South Korea created a handheld photoacoustic detector that may be used to monitor lymph node status without exposing patients to radiation in September 2021.

Recent Development

In September 2020, Advantest announced the Hadatomo Z Photoacoustic Microscope WEL5200, which features a high-resolution ultrasonic sensor. It uses two wavelengths of optical ultrasound to identify pictures that resemble the saturation state of oxygen in blood arteries. Ultrasound can also be used to examine images of skin texture, pores, and structures such as sebum glands.

iThera Medical introduced its new inVision TRIO preclinical optoacoustic imaging device in October 2021. The inVision TRIO is the first imaging system in the world to feature transmission ultrasonic computed tomography (TUCT), expanding the spectrum of biomedical applications provided by iThera Medical's optoacoustic imaging systems.

Vevo F2, the world's first ultrahigh-to-low-frequency ultrasound imaging system with a frequency range of 71-1 MHz, was introduced in June 2020 by FUJIFILM VisualSonics Inc, a subsidiary of FUJIFILM SonoSite, Inc.

COVID-19 Impact

The COVID-19 outbreak had a relatively negative effect on the photoacoustic imaging market. The COVID-19 epidemic has caused significant problems for the healthcare system. The pandemic has influenced the worldwide healthcare supply chain. The photoacoustic imaging business has been harmed by a global shortage of medical care services for illnesses other than COVID-19. Furthermore, due to decreased demand, postponed clinical and pre-clinical trials, and widespread financial difficulty, several country governments placed regulatory limitations, resulting in a lower deployment of photoacoustic imaging devices. Many pre-clinical and clinical investigations were resumed in 2021 as social limitations were eased, which is predicted to boost demand for photoacoustic imaging.

Segmentation

• By Product

Photoacoustic Tomography

Photoacoustic Microscopy

• By Type

Pre-clinical

Clinical

• By Application

Oncology

Cardiology

Angiology

Histology

Interventional Radiology

Other Applications

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of End-Users
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Photoacoustic Imaging Market Analysis, by Product

• 5.1. Introduction
• 5.2. Photoacoustic Tomography
• 5.3. Photoacoustic Microscopy

6. Photoacoustic Imaging Market Analysis, by Type

• 6.1. Introduction
• 6.2. Pre-clinical
• 6.3. Clinical

7. Photoacoustic Imaging Market Analysis, by Application

• 7.1. Introduction
• 7.2. Oncology
• 7.3. Cardiology
• 7.4. Angiology
• 7.5. Histology
• 7.6. Interventional Radiology
• 7.7. Other Applications 

8. Photoacoustic Imaging Market Analysis, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. Israel
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Taiwan
  • 8.6.8. Others 

9. Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

• 10.1. Advantest Corp.
• 10.2. TomoWave
• 10.3. Kibero GmbH
• 10.4. FUJIFILM VisualSonics Inc.
• 10.5. Seno Medical Instruments
• 10.6. iThera Medical GmbH
• 10.7. Aspectus GmbH
• 10.8. Vibronix Inc.
• 10.9. ENDRA Life Sciences Inc.
• 10.10. PA Imaging R&D B.V.